KIT and systemic mastocytosis: Therefore, it was proposed that ddPCR-based measurement of KIT D816V mutation burden in FFPE BM tissue sections, as a new promising prognostic and minimal residual disease biomarker, should be included in all future studies of prognosis and therapy of SM [77].